Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Lockheed Martin Corporation — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Lockheed Martin Corporation trades at $525.25 (market cap $116.32B). The key difference: Lockheed Martin Corporation is far larger — about 13.1× Kymera Therapeutics Inc. Common Stock's market cap, and Lockheed Martin Corporation pays a 2.86% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Lockheed Martin Corporation for 86 Days on average.
| KYMR | LMT | |
|---|---|---|
Market Cap | $8.87B | $116.32B |
Volume | 779,107 | 860,316 |
Sector | Health | Industrials |
52-Week High | $127.31 | $676.70 |
52-Week Low | $55.80 | $439.19 |
Typical Hold Time | 0 Days | 86 Days |
Enterprise Value | $8.26B | $133.07B |
Dividend Yield | — | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lockheed Martin (LMT) trades at $522.23, up 2.02% today, with a bearish technical signal and neutral oscillators. The company reported revenue of $75.05 billion in 2025, with net income of $5.02 billion, though recent quarters show mixed earnings results. Analysts maintain a strong buy consensus with a $625.64 price target. Recent news highlights ongoing dividend increases, AI integration efforts, and new defense contracts, supporting long-term growth prospects amid stable cash flows.
The outlook for LMT is positive, driven by robust defense spending and strategic innovations, but risks include reliance on government contracts and fixed-price contract volatility. The stock offers value with a P/E of 18.58 and a dividend yield supported by 23 years of increases, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
